Eurofins Scientific SE (Eurofins Scientific SE) Debt-to-Equity : 0.77 (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Eurofins Scientific SE Debt-to-Equity?

Eurofins Scientific SE's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $655 Mil. Eurofins Scientific SE's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $3,626 Mil. Eurofins Scientific SE's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $5,537 Mil. Eurofins Scientific SE's debt to equity for the quarter that ended in Dec. 2023 was 0.77.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Eurofins Scientific SE's Debt-to-Equity or its related term are showing as below:

ERFSF' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.59 Med: 0.88 Max: 1.79
Current: 0.77

During the past 13 years, the highest Debt-to-Equity Ratio of Eurofins Scientific SE was 1.79. The lowest was 0.59. And the median was 0.88.

ERFSF's Debt-to-Equity is ranked worse than
78.17% of 197 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.22 vs ERFSF: 0.77

Eurofins Scientific SE Debt-to-Equity Historical Data

The historical data trend for Eurofins Scientific SE's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eurofins Scientific SE Debt-to-Equity Chart

Eurofins Scientific SE Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

1.25

0.86

0.59

0.70

0.77

Eurofins Scientific SE Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.59	0.71	0.70	0.66	0.77

Competitive Comparison of Eurofins Scientific SE's Debt-to-Equity

For the Diagnostics & Research subindustry, Eurofins Scientific SE's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eurofins Scientific SE's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Eurofins Scientific SE's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Eurofins Scientific SE's Debt-to-Equity falls into.

Eurofins Scientific SE Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Eurofins Scientific SE's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(655.398	+	3626.499)	/	5537.077
	=	0.77

Eurofins Scientific SE's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(655.398	+	3626.499)	/	5537.077
	=	0.77

Eurofins Scientific SE (OTCPK:ERFSF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Eurofins Scientific SE Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Eurofins Scientific SE's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Eurofins Scientific SE (Eurofins Scientific SE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Eurofins Scientific SE (OTCPK:ERFSF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

ERFp:UK 0MV5:UK ERF:France ESF0:Germany

Address

23 Val Fleuri, Luxembourg, LUX, L-1526

Website

https://www.eurofins.com

Eurofins, headquartered in Luxembourg, is a decentralized network of life sciences companies that provide various analytical tests and laboratory services. These include tests to evaluate the safety, identity, composition, authenticity, purity, origin, and traceability of various biological substances and products. Eurofins operates over 900 laboratories in 61 countries. Its revenue from Europe, North America, and the Rest of the World contribute approximately 50%, 40%, and 10% of total revenue respectively. Its main business activities are food and environmental testing, biopharmaceutical services, diagnostic services and products, and consumer and technology products testing, which contribute approximately 40%, 30%, 20%, and 10% respectively.